301130.SHE Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
- Market cap
- CNY 1.78B
- P/E
- -
- P/B
- 2.05x
- ROE
- 1.0%
- Dividend yield
- 1.14%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301130.SHE undervalued?
Graham numberThe Graham number of Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd fundamental analysis
No fundamental analysis for Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd yet.
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research, development, production, and sales of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anti-anemia, mental disorders, circulatory disorders, anti-psychotic, active pharmaceutical ingredients, and antidepressant medication. It also provides iron supplements and blood tonics; psychotropic drugs; cardiovascular system medicat…
Full company profileJilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 204M | 274M | 280M | 325M | 286M | 286M | 255M | 225M | 256M | 235M | 199M |
| Gross Profit | 174M | 238M | 241M | 278M | 242M | 239M | 208M | 180M | 195M | 179M | 144M |
| Operating Income | 55.0M | 54.2M | 48.5M | 65.4M | 59.2M | 59.7M | 52.1M | 55.7M | 46.3M | 17.1M | 4.77M |
| EBITDA | 44.6M | 67.7M | 66.3M | 85.1M | 79.4M | 78.0M | 68.9M | 76.9M | 69.0M | 56.9M | 6.10M |
| Net Income | 50.9M | 45.6M | 41.4M | 54.6M | 49.7M | 52.0M | 40.7M | 50.5M | 40.3M | 21.9M | 8.64M |
| EPS | 0.94 | 0.80 | 0.68 | 0.90 | 0.82 | 0.86 | 0.53 | 0.63 | 0.52 | 0.29 | 0.11 |
| Balance Sheet | |||||||||||
| Total Assets | 284M | 471M | 502M | 531M | 551M | 595M | 1.02B | 1.07B | 1.06B | 1.06B | 1.06B |
| Total Liabilities | 55.1M | 89.9M | 91.5M | 84.1M | 78.6M | 70.5M | 71.7M | 84.3M | 121M | 127M | 163M |
| Shareholders' Equity | 229M | 381M | 410M | 447M | 472M | 524M | 945M | 983M | 906M | 904M | 869M |
| Cash & Short-term Investments | 11.7M | 93.4M | 116M | 101M | 108M | 214M | 616M | 548M | 276M | 29.5M | 78.3M |
| Total Debt | 3.50M | - | - | - | - | - | - | 198K | 10.1M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | - | 31.3M | 66.1M | 65.9M | 64.5M | 59.0M | 67.2M | 54.4M | 54.2M | 48.6M | - |
| Capital Expenditure | 50.7M | 44.2M | 31.1M | 13.2M | 14.5M | 21.2M | 54.4M | 123M | 135M | 66.1M | 50.2M |
| Free Cash Flow | -50.7M | -12.9M | 35.0M | 52.7M | 50.0M | 37.8M | 12.8M | -68.8M | -80.7M | -17.4M | 7.35M |
| Ratios | |||||||||||
| ROE | 22.2% | 12.0% | 10.1% | 12.2% | 10.5% | 9.9% | 4.3% | 5.1% | 4.4% | 2.4% | 1.0% |
| ROA | 17.9% | 9.7% | 8.2% | 10.3% | 9.0% | 8.7% | 4.0% | 4.7% | 3.8% | 2.1% | 0.8% |
| Net Profit Margin | 25.0% | 16.7% | 14.8% | 16.8% | 17.4% | 18.2% | 15.9% | 22.4% | 15.7% | 9.3% | 4.3% |
| Debt to Equity | 0.02x | - | - | - | - | - | - | 0.00x | 0.01x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd dividends
- Dividend yield
- 1.14%
- Forward dividend
- 0.15 CNY
- Payout ratio
- 92.8%
- Ex-dividend date
- Jun 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 20.3M | 0.27 | 92.8% |
| 2024 | CNY 20.0M | 0.26 | 49.7% |
| 2023 | CNY 12.9M | 0.16 | 25.6% |
| 2022 | CNY 10.5M | 0.14 | 25.8% |
| 2021 | - | - | - |
| 2020 | CNY 24.2M | 0.40 | 48.7% |
| 2019 | CNY 18.2M | 0.30 | 33.3% |
| 2018 | 12.1M | 0.20 | 29.3% |
| 2017 | 10.8M | 0.19 | 23.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
- Insiders 48.68%
- Institutions 11.56%
- Public & others 39.77%
- Shares outstanding 76.5M
- Free float 41.8M
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd company profile
- Company name
- Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
- Ticker
- 301130.SHE
- ISIN
- CNE1000058C4
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Chemicals
- Employees
- 313
- Fiscal year end
- December
- Address
- No. 777, Xidian Street, Panshi, China, 132300
- Phone
- 86 43 2658 88200
- Website
- xidianyy.com
About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd engages in the research, development, production, and sales of chemical raw materials and pharmaceutical preparations in China. The company provides drugs for the treatment of anti-anemia, mental disorders, circulatory disorders, anti-psychotic, active pharmaceutical ingredients, and antidepressant medication. It also provides iron supplements and blood tonics; psychotropic drugs; cardiovascular system medication; medication for chronic diseases in the elderly; cancer adjuvant drugs; cardiovascular and cerebrovascular drugs; cold medicine; and other products. The company was founded in 1990 and is headquartered in Panshi, China.
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.Ltd management
6- Mr. Jun ZhangChairman of the Board & GM · born 1956
- Mr. Si MengFinancial Director · born 1987
- Mr. Shiying XiuDirector & Deputy GM · born 1961
- Mr. Yonghong MengDirector & Deputy GM · born 1960
- Ms. Yinji ZhangDeputy GM & Secretary · born 1977
- Xiang Ru WeiAccounting Supervisor